Pleomorphic xanthoastrocytoma with invasion of the tentorium and falx.

Surg Neurol

Section of Neurosurgery, University of Puerto Rico, San Juan 00936, USA.

Published: January 1995

A case of a 21-year-old patient with a recurrent pleomorphic xanthoastrocytoma with invasion of the tentorium and falx cerebri is reported. Dural attachment has been reported in some cases. Invasion of the dura of the falx cerebri and complete infiltration of the left tentorium by the tumor were found intraoperatively. This is the first case in the literature which shows invasion of the dura in a pleomorphic xanthoastrocytoma.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0090-3019(95)80044-hDOI Listing

Publication Analysis

Top Keywords

pleomorphic xanthoastrocytoma
12
xanthoastrocytoma invasion
8
invasion tentorium
8
tentorium falx
8
falx cerebri
8
invasion dura
8
invasion
4
falx case
4
case 21-year-old
4
21-year-old patient
4

Similar Publications

Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery.

Curr Oncol

December 2024

Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.

Glioblastoma (GBM) is a primary central nervous system malignancy with a median survival of 15-20 months. The presence of both intra- and intertumoral heterogeneity limits understanding of biological mechanisms leading to tumor resistance, including immune escape. An attractive field of research to examine treatment resistance are immune signatures composed of cluster of differentiation (CD) markers and cytokines.

View Article and Find Full Text PDF

Glioblastoma (GBM) is a highly aggressive brain tumor characterized by its ability to evade the immune system, hindering the efficacy of current immunotherapies. Recent research has highlighted the important role of immunosuppressive macrophages in the tumor microenvironment (TME) in driving this immune evasion. In this study, we are the first to identify as a key regulator of tumor-associated macrophage (TAM)-mediated immunosuppression in GBM.

View Article and Find Full Text PDF

The latest World Health Organization (WHO) classification of central nervous system tumors (WHO2021/5th) has incorporated molecular information into the diagnosis of each brain tumor type including diffuse glioma. Therefore, an artificial intelligence (AI) framework for learning histological patterns and predicting important genetic events would be useful for future studies and applications. Using the concept of multiple-instance learning, we developed an AI framework named GLioma Image-level and Slide-level gene Predictor (GLISP) to predict nine genetic abnormalities in hematoxylin and eosin sections: , , mutations, promoter mutations, homozygous deletion (CHD), amplification (amp), 7 gain/10 loss (7+/10-), 1p/19q co-deletion, and promoter methylation.

View Article and Find Full Text PDF

Background: Glioblastoma multiforme (GBM) is one of the deadliest and most heterogeneous forms of brain cancer, characterized by its resistance to conventional therapies. Within GBM, a subpopulation of slow-cycling cells, often linked to quiescence and stemness, plays a crucial role in treatment resistance and tumor recurrence. This study aimed to identify novel biomarkers associated with these slow-cycling GBM cells.

View Article and Find Full Text PDF

The intricate relationship between SUMOylation and gliomas: a review with a perspective on natural compounds.

Nat Prod Res

January 2025

Programa de Pós-Graduação em Biologia Celular e do Desenvolvimento, Universidade Federal de Santa Catarina, Florianópolis, Brazil.

Gliomas are tumours that affect the nervous system, with glioblastoma, also known as grade IV astrocytoma, being the most aggressive type, associated with poor prognosis. Glioblastoma is characterised by its highly invasive nature, rapid growth, and resistance to conventional chemotherapy and radiation treatments, resulting in a median survival of about 14 months. To improve patient outcomes, novel therapeutic approaches are needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!